EMAS Pharma sold by Bionical Emas to Kester Capital following strategic review

Bionical Emas Strengthens Leadership in Early Access Programs and Clinical Trial Supply Bionical Emas, a global frontrunner in Early Access Programs (EAP) and Clinical Trial Supply (CTS), is set to reinforce its market position by focusing sharply on its core…